3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
Abstract
A compound selected from the group consisting of: 3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-methoxypropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; Ethyl {4- (aminocarbonyl) -3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] isothiazol-5-yl} carbamate; 3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4- carboxamide; 3- {4- [3- (2-Fluoro-5-methyl-phenyl) -ureido] -2-methyl-phenyl} -5- [3- (3-morpholin-4-yl-propyl) - acid amide ureido] -isothiazole-4-carboxylic; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-methyl-phenyl) -ureido] -phenyl} -isothiazol-5-yl) -ureido] -propionic acid; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-methyl-phenyl) -ureido] -2-methyl-phenyl} -isothiazol-5-yl) -ureido] acid -propionic; 3- [4 - ({[(3-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; 3- [2-methyl-4- (3-m-tolyl-ureido) -phenyl] -5- [3- (3-morpholin-4-yl-propyl) -ureido] -isothiazole-4-carboxylic acid amide ; 3- (3- {4-carbamoyl-3- [4- (3-m-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- (3- {4-carbamoyl-3- [2-methyl-4- (3-m-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- {4 - [({[2-fluoro-5- (trifluoromethyl) phenyl] amino} carbonyl) amino] phenyl} -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole -4-carboxamide; 3- {4- [3- (2-Fluoro-5-trifluoromethyl-phenyl) -ureido] -2-methyl-phenyl} -5- [3- (3-morpholin-4-yl-propyl) - acid amide ureido] -isothiazole-4-carboxylic; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-trifluoromethyl-phenyl) -ureido] -phenyl} -isothiazol-5-yl) -ureido] -propionic acid; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-trifluoromethyl-phenyl) -ureido] -2-methylphenyl} -isothiazol-5-yl) -ureido] -propionic acid ; 3- {4 - [(anilinocarbonyl) amino] phenyl} -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; 3- [2-methyl-4- (3-phenyl-ureido) -phenyl] -5- [3- (3-morpholin-4-yl-propyl) -ureido] -isothiazole-4-carboxylic acid amide; 3- (3- {4-carbamoyl-3- [4- (3-phenyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- (3- {4-carbamoyl-3- [2-methyl-4- (3-phenyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; 3- [2-methyl-4- (3-p-tolyl-ureido) -phenyl] -5- [3- (3-morpholin-4-yl-propyl) -ureido] -isothiazole-4-carboxylic acid amide ; 3- (3- {4-carbamoyl-3- [2-methyl-4- (3-p-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- (3- {4-carbamoyl-3- [4- (3-p-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) -3- (4 - {[3- (trifluoromethyl) benzoyl] amino} phenyl) isothiazole-4-carboxamide; 3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] -5 - {[(2-oxopyrrolidin-1-yl) carbonyl] amino} isothiazole-4-carboxamide; 4 - {[({4- (aminocarbonyl) -3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazol-5-yl} amino) carbonyl] amino} butanoic acid; Methyl 4 - {[({4- (aminocarbonyl) -3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazol-5-yl} amino) carbonyl] amino} butanoate; 5 - ({[(3-hydroxypropyl) amino] carbonyl} amino) -3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazole-4-carboxamide; 5-amino-3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazole-4-carboxamide; 5-amino-3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] isothiazole-4-carboxamide; and 3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-pyrrolidin-1-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; or a pharmaceutically acceptable salt thereof.
Term
6.3 yearsto projected expiry
Projected expiry 27 December 2032, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
9 members in 4 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 201161581031 | United States of America | P | |
| 201161581031 | United States of America | P | |
| 201161581031P | United States of America | – | |
| 201161581031P | – | – | – |
| US201161581031P | – | – | – |
Members9
| Document | Office | Kind | |
|---|---|---|---|
| US2013172353A1 | United States of America | A1 | |
| WO2013101954A1 | World Intellectual Property Organization (WIPO) | A1 | |
| EP2797916A1 | European Patent Office (EPO) | A1 | |
| US8969583B2 | United States of America | B2 | |
| EP2797916B1 | European Patent Office (EPO) | B1 | |
| EP3184525A1 | European Patent Office (EPO) | A1 | |
| ES2623652T3 | Spain | T3 | |
| EP3184525B1 | European Patent Office (EPO) | B1 | |
| ES2851602T3This record | Spain | T3 |
Numbers
- Publication
- 2851602
- Publication, DOCDB
- 2851602
- Publication, EPODOC
- ES2851602T
- Application
- 17156014
- Application, DOCDB
- 17156014
- Application, EPODOC
- ES20170156014T
Titles2
- Spanish
- Derivados de 3-fenil-5-ureidoisotiazol-4-carboxamida como inhibidores de cinasa
- English
- 3-Phenyl-5-ureidoisothiazole-4-carboxamide derivatives as kinase inhibitors
Classification
- CPC, 5
- C07D417/12
- A61P3/00
- A61P35/00
- C07D275/03
- C07D295/13
- IPC, 7
- C07D417 12
- A61K31 425
- A61K31 427
- A61P3 00
- A61P35 00
- C07D275 03
- C07D295 13